Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Koninklijke Philips N.V. is a Dutch multinational health technology company founded in 1891, headquartered in Amsterdam, Netherlands. Originally starting with light bulb production, it has transformed into a leader in advancing healthcare through innovative solutions that span the health continuum from prevention and diagnosis to treatment and home care. The company operates through three main segments: Diagnosis & Treatment, featuring precision diagnostics and image-guided therapy like MRI, CT, and ultrasound scanners; Connected Care, encompassing patient monitoring, sleep and respiratory care, and health informatics; and Personal Health, offering products such as electric toothbrushes, shavers, and baby care items. With approximately 68,000 employees, operations in over 100 countries, and around 53,000 patents, Koninklijke Philips N.V. invests about 9-10% of its revenue—roughly €18 billion in 2024—into research and development. Its mission focuses on improving 2.5 billion lives annually by 2030, including underserved communities, solidifying its pivotal role in global medtech innovation and patient outcomes.
Operating margin is thin at 8.12%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue declined 1.0% YoY. The question is whether this is cyclical or a structural shift.
Free cash flow declined 44% versus the prior year, cash generation momentum has weakened. Net debt of €5.02B represents 10.0x FCF, leverage limits flexibility.
Profitability & Returns
Revenue (TTM)
€17.64B
▼ -1.0% YoY
Net Income (TTM)
€971M
▲ +228.5% YoY
Op. Margin
8.72%
▲ +5.3pp YoY
ROIC
5.76%
▲ +4.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€1.62B
▼ -43.6% YoY
Op. Cash Flow (TTM)
€2.56B
▼ -16.3% YoY
Net Debt
€5.02B
Cash & Equiv.
€2.79B
3Y CAGR: +0.0%
Continue Research